Bendamustine lymphodepletion before axicabtagene ciloleucel is safe and associates with reduced inflammatory cytokines.

MLA

Ghilardi, Guido, et al. “Bendamustine Lymphodepletion before Axicabtagene Ciloleucel Is Safe and Associates with Reduced Inflammatory Cytokines.” Blood Advances, vol. 8, no. 3, Feb. 2024, pp. 653–66. EBSCOhost, https://doi.org/10.1182/bloodadvances.2023011492.

APA

Ghilardi, G., Paruzzo, L., Svoboda, J., Chong, E. A., Shestov, A. A., Chen, L., Cohen, I. J., Gabrielli, G., Nasta, S. D., Porazzi, P., Landsburg, D. J., Gerson, J. N., Carter, J., Barta, S. K., Yelton, R., Pajarillo, R., Patel, V., White, G., Ballard, H. J., … Ruella, M. (2024). Bendamustine lymphodepletion before axicabtagene ciloleucel is safe and associates with reduced inflammatory cytokines. Blood Advances, 8(3), 653–666. https://doi.org/10.1182/bloodadvances.2023011492

Chicago

Ghilardi, Guido, Luca Paruzzo, Jakub Svoboda, Eise A Chong, Alexander A Shestov, Linhui Chen, Ivan J Cohen, et al. 2024. “Bendamustine Lymphodepletion before Axicabtagene Ciloleucel Is Safe and Associates with Reduced Inflammatory Cytokines.” Blood Advances 8 (3): 653–66. doi:10.1182/bloodadvances.2023011492.